Overall Fundamental outlook

|fundrankingplaceholder|
|techrankingplaceholder|

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for GLAXO
Revenue projections for GLAXO

With GLAXO's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 2.02700
forwardPE 29.53607
debtToEquity 1.46700
earningsGrowth 0.05700
revenueGrowth 0.02100
grossMargins 0.64647
operatingMargins 0.33935
trailingEps 60.03000
forwardEps 77.27500

GLAXO's current ratio is 2.027, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting GLAXO has no trouble covering its short-term financial obligations.
GLAXO's Forward PE ratio is in a good range, reflecting a reasonable balance between stock price and earnings. The stock is not overpriced, leaving room for growth, which suggests potential for investors looking to capitalize on future value appreciation.
GlaxoSmithKline Pharmaceuticals Limited's positive gross and operating margins suggest strong profitability. These margins reflect effective cost management and revenue generation, indicating that the company is efficiently managing its operations and maintaining financial health.
GlaxoSmithKline Pharmaceuticals Limited's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that GlaxoSmithKline Pharmaceuticals Limited is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for GLAXO
Price projections for GLAXO

The current price of GlaxoSmithKline Pharmaceuticals Limited, in relation to its projections, presents a neutral outlook. There are no discernible risks or opportunities at this stage, indicating that investors may need to await further developments to make informed decisions regarding their positions in the stock.

Recommendation changes over time:

Recommendations trend for GLAXO
Recommendations trend for GLAXO


With analysts showing a buy bias for GlaxoSmithKline Pharmaceuticals Limited, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning GlaxoSmithKline Pharmaceuticals Limited as a safe and profitable place for investors to allocate their funds and seek growth.